Equities

Citius Pharmaceuticals Inc

Citius Pharmaceuticals Inc

Actions
  • Price (EUR)0.374
  • Today's Change-0.062 / -14.22%
  • Shares traded2.50k
  • 1 Year change-46.26%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Sep 30 2023202320222021
ASSETS
Cash And Short Term Investments264270
Total Receivables, Net------
Total Inventory------
Prepaid expenses7.892.852.74
Other current assets, total------
Total current assets344573
Property, plant & equipment, net0.460.650.83
Goodwill, net9.359.359.35
Intangibles, net595959
Long term investments------
Note receivable - long term------
Other long term assets0.040.040.04
Total assets104114142
LIABILITIES
Accounts payable2.931.171.28
Accrued expenses2.853.362.71
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total------
Total current liabilities5.784.533.98
Total long term debt000
Total debt000
Deferred income tax6.145.564.99
Minority interest0.600.600.60
Other liabilities, total0.260.480.68
Total liabilities131110
SHAREHOLDERS EQUITY
Common stock0.160.150.15
Additional paid-in capital253232228
Retained earnings (accumulated deficit)(162)(130)(96)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity91103132
Total liabilities & shareholders' equity104114142
Total common shares outstanding159146146
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.